Related Experiment Video
Updated: Jun 26, 2026

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
Published on: December 11, 2017
Nine-year routine clinical experience of aortic valve replacement with ATS mechanical valves
Jean-Pierre Villemot1, Malik Lekehal, Pablo Maureira
1Department of Cardiothoracic Surgery and Transplantation, University-Hospital of Nancy-Brabois, Vandoeuvre-lès-Nancy, France. jp.villemot@chu-nancy.fr
Insights
The ATS mechanical valve shows good early and long-term outcomes in aortic valve replacement (AVR) patients. Survival rates are favorable, with low rates of complications like thromboembolism and bleeding.
Area of Science:
- Cardiac Surgery
- Biomaterials and Medical Devices
- Cardiovascular Medicine
Background:
- Aortic valve replacement (AVR) is a critical procedure for managing aortic valve disease.
- Mechanical prostheses are widely used, with the ATS valve being a common choice.
- Understanding long-term outcomes is essential for patient selection and management.
Purpose of the Study:
- To evaluate the early and long-term outcomes of aortic valve replacement (AVR) using the ATS mechanical prosthesis.
- To assess the performance of the ATS valve in a routine clinical practice setting.
- To identify factors influencing patient survival and complications after AVR.
Main Methods:
- Retrospective analysis of clinical data from 510 consecutive patients undergoing AVR with the ATS mechanical prosthesis (1996-2005).
- Patients included isolated AVR and those with concomitant procedures (CABG, MVP, AAR).
- Analysis of early and late morbidity/mortality, considering emergency surgery, low ejection fraction, and advanced age.
Main Results:
- Overall 30-day mortality was 7.2%, with variations based on concomitant procedures.
- Five- and nine-year survival rates were 81.14% and 67.02%, respectively.
- Lower long-term survival was observed in emergency cases, low LVEF (<50%), and patients aged ≥70 years. Postoperative valve-related death was 1.1%/pt-yr, with low rates of thromboembolism (0.4%/pt-yr) and bleeding (0.63%/pt-yr). No valve thrombosis, structural dysfunction, or endocarditis were reported.
Conclusions:
- The ATS mechanical valve demonstrates globally very good performance in AVR.
- Outcomes are comparable to previously reported results for mechanical valves.
- The study supports the continued use of the ATS valve in clinical practice.
Background And Aim Of The Study:
The study aim was to update the authors' experience with aortic valve replacement (AVR) using the ATS mechanical prosthesis in terms of early and long-term outcome in routine practice.
Methods:
This retrospective analysis was extracted from clinical data available between April 1996 and February 2005, of AVR with the ATS Medical prosthesis in 510 consecutive patients (345 men, 165 women; mean age 62 +/- 12 years), of whom 296 underwent isolated AVR (iAVR). Concomitant surgical procedures included coronary artery bypass grafting (AVR+CABG, n = 47), mitral valve procedure (AVR+MVP, n = 59), ascending aortic replacement (AVR+AAR, n = 74) and other procedures (AVR+Miscellaneous, n = 34). Early and late morbidity/mortality were analyzed for the entire group in case of emergency surgery, preoperative low left ventricular ejection fraction (LVEF <50%) and in elderly people (age > or = 70 years).
Results:
The overall 30-day mortality was 7.2% (iAVR 4.7%; AVR+CABG 4%; AVR+MVP 8.5%; AVR+AAR 2.9%; AVR+Miscellaneous 14.7%). The five- and nine-year global survival rates were respectively 81.14 +/- 2.4% and 67.02 +/- 10.4%. Long-term survival was lower in case of emergency surgery (p = 0.001), when the preoperative LVEF was <50% (p = 0.03), and when patients were aged > or = 70 years (p = 0.0005). Linearized postoperative valve-related death was 1.1% per patient-year (pt-yr). However, nine years' freedom from valve-related death and valve-related morbidity were not significantly different when the patient age was > or = 70 years. The linearized rate for postoperative thromboembolism complication was 0.4% per pt-yr, and that for postoperative bleeding complication 0.63% per pt-yr. There were two perivalvular leaks (0.05%/pt-yr). Neither valve thrombosis, structural dysfunction nor endocarditis were observed.
Conclusion:
The findings of this retrospective study point to a globally very good performance of the ATS valve, and essentially similar to previously reported results with these and other available mechanical valves.
More Related Videos
Related Concept Videos
Aortic Regurgitation I: Introduction
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aortic Regurgitation IV: Nursing Management

